HEPA Hepion Pharmaceuticals Inc

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Schedule 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

(Amendment No. )

 

Filed by the Registrant x

 

Filed by a party other than the Registrant ¨

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement

 

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨ Definitive Proxy Statement

 

x Definitive Additional Materials

 

¨ Soliciting Material under § 240.14a-12

 

Hepion Pharmaceuticals, Inc.

 

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

x No fee required

 

¨ Fee paid previously with preliminary materials.

 

¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

 

 

 

 

 

June 29, 2022

 

Dear Stockholder:

 

We have previously sent to you proxy material for the annual meeting of stockholders of Hepion Pharmaceuticals, Inc. (the “Annual Meeting”), which was held on June 24, 2022. The Annual Meeting has been adjourned to Friday, July 22, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4 (Authorized Share Increase) to allow those stockholders who have not yet done so more time to vote.

 

The hurdle is high; securing affirmative votes from a majority of the outstanding shares entitled to vote. However, so are the stakes; the ability to continue to advance rencofilstat, our lead oral drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

 

Two leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS’) and Glass Lewis and Co. LLC (“Glass Lewis”), have both affirmed our Board of Directors’ recommendation that stockholders vote “FOR” Proposal 4. The voting recommendations of ISS and Glass Lewis are relied upon by institutional investment firms, mutual funds, and other fiduciaries globally for independent advice on shareholder voting and corporate governance.

 

ISS and Glass Lewis based their recommendations on the requested increase in authorized common shares being deemed reasonable, and Hepion’s prudent use of its shares historically. Notably, Proposal 4 contains no anti-dilution adjustments for management and/or investors.

 

If you have already voted your shares “FOR” Proposal 4, you do not need to vote again, and we thank you for your support. If you did not vote at all, abstained from voting for, or voted against with respect to the proposal, we kindly ask you to vote, or to reconsider your vote

 

Very truly yours,

 

Gary S. Jacob

Chairman of the Board of Directors